Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	27.74B +35.0%
Revenue (ttm)	4.92B -32.7%
Net Income	2.13B -4.4%
EPS	2.77 -4.2%
Shares Out	770.09M
PE Ratio	14.82
Forward PE	28.12
Dividend	1.28 (3.08%)
Ex-Dividend Date	Feb 12, 2026

Volume	2,697,100
Average Volume	4,303,226
Open	41.38
Previous Close	41.55
Day's Range	40.95 - 41.65
52-Week Range	29.19 - 50.97
Beta	0.74
RSI	43.81
Earnings Date	Mar 31, 2026

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2025, SHA:600329's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.